Incremental clinical and economic burden of suspected respiratory infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States

ConclusionsCompared with suspected infections due to non-MDR P. aeruginosa, patients with MDR P. aeruginosa had higher risk of mortality, readmission, and longer LOS, as well as US$20,000 incremental cost and>US$10,000 incremental net loss per case after controlling for patient and hospital characteristics.
Source: Journal of Hospital Infection - Category: Infectious Diseases Source Type: research